Efficacy of suramin against human prostate carcinoma DU145 xenografts in nude mice

Cancer Chemotherapy and Pharmacology

Volumn 43, Issue 3, 1999, Pages 198-204

  Church, Dawn ^a   Zhang, Yunlei ^b   Rago, Randall ^c   Wilding, George ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

^b Stony Brook University   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Nude mice; Prostate cancer; Suramin

Indexed keywords

SURAMIN;

ADVANCED CANCER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CORTICOSTEROID THERAPY; DATA ANALYSIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; TREATMENT PLANNING; TUMOR VOLUME; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; PROSTATIC NEOPLASMS; SURAMIN; TRANSPLANTATION, HETEROLOGOUS;

EID: 0032894935     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050884     Document Type: Article

References (26)

1. Bai L, Naomoto Y, Miyazaki M, Orita K, Namba M (1992) Antiproliferative effects of suramin on human cancer cells in vitro and in vivo. Acta Med Okayama 46: 457
2. Chang SY, Yu DS, Sherwood ER, Kozlowski JM, Lee C (1992) Inhibitory effects of suramin on a human renal cell carcinoma line, causing nephrogenic hepatic dysfunction. J Urol 147: 1147
3. Clark JW, Chabner BA (1995) Suramin and prostate cancer: where do we go from here? (editorial). J Clin Oncol 13: 2155
4. Eisenberger MA, Reyno LM (1994) Suramin. Cancer Treat Rev 20: 259
5. Geran RI, Greenberg NH, MacDonald MM, Schumacher AM, Abbott BJ (1972) Protocols for screening chemical agents and natural products against animal tumors and other biological systems. Cancer Chemother Rep 3 (part 3): 1
6. Hutson PR, Tutsch K, Spriggs D, Christian M, Rago R, Mutch R, Wilding G (1993) Evidence of an absorption phase after short intravenous suramin infusions. Cancer Chemother Pharmacol 31: 495
7. Hutson PR, Tutsch KD, Rago R, Arzoomanian R, Alberti D, Pomplun M, Church D, Marnocha R, Spriggs D, Cheng A, Kehrli N, Wilding G (1998) Renal clearance, tissue distribution, and CA-125 responses in a phase I trial of suramin. Clin Cancer Res 4: 1429-1436
8. Kelly WK, Scher HI (1994) Prostate cancer: how can a common disease be so controversial? Curr Opin Oncol 6: 318
9. Klecker R Jr, Collins J (1985) Quantification of suramin by reverse-phase ion-pairing high-performance liquid chromatography. J Liq Chromatogr 8: 1685
10. Landis SH, Murray T, Bolden S, Wingo PA (1998) Cancer statistics, 1998. CA Cancer J Clin 48: 6
11. Leith JT, Papa G, Quaranto L, Michelson S (1992) Modification of the volumetric growth responses and steady-state hypoxic fractions of xenografted DLD-2 human colon carcinomas by administration of basic fibroblast growth factor or suramin. Br J Cancer 66: 345
12. Milliken GA, Johnson DE (1984) Analysis of repeated measures designs for which the usual assumptions hold. In: Milliken GA, Johnson DE (eds) Analysis of messy data, vol 1: designed experiments. Lifetime Learning Publications, Belmont, pp 322-351
13. Milliken GA, Johnson DE (1984) Analysis of repeated measures designs for which the usual assumptions do not hold. In: Milliken GA, Johnson DE (eds) Analysis of messy data, vol 1: designed experiments. Lifetime Learning Publications, Belmont, pp 352-377
14. Mitchen J, Rago R, Wilding G (1993) Effects of suramin on the proliferation of primary epithelial cell cultures derived from normal, benign hyperplastic and cancerous human prostates. Prostate 22: 75
15. Morton RA, Isaacs JT, Isaacs WB (1990) Differential effects of growth factor antagonists on neoplastic and normal prostatic cells. Prostate 17: 327
16. Rago R, Church D, Wilding G (1994) Suramin- or colchicine-resistant cells and sensitivity to vinblastine and suramin (meeting abstract). Proceedings of the Annual Meeting of the American Association for Cancer Research 35: A1956
17. Roberts BJ, Hook KE, Whitfield LR, Elliot WL, Dykes DJ, Carter CA, Waud WR (1995) Lack of efficacy of suramin against orthotopically implanted LNCaP and PC-3 prostate tumor xenografts at clinically relevant blood levels (meeting abstract). Proceedings of the Annual Meeting of the American Association for Cancer Research 36: A1613
18. Rosen PJ, Mendoza EF, Landaw EM, Mondino B, Graves MC, McBride JH, Turcillo P, deKernion J, Belldegrun A (1996) Suramin in hormone-refractory metastatic prostate cancer: a drug with limited efficacy. J Clin Oncol 14: 1626
19. Saffrin R, Chou P, Ray V, Shaw M, Rubenstein M, Guinan P (1996) Suramin as adjuvant therapy with radical prostatectomy. Prostate 28: 325
20. Small EJ, Marshall ME, Reyno L, Meyers F, Natale R, Meyer M, Lenehan P, Chen L, Eisenberger M (1998) Superiority of suramin + hydrocortisone (S + H) over placebo + hydrocortisone (P + H): results of a multi-center double-blind phase III study in patients with hormone refractory prostate cancer (HRPC) (meeting abstract). Proceedings of the Annual Meeting of the American Society of Clinical Oncology 17: A1187
21. Stein CA (1993) Suramin: a novel antineoplastic agent with multiple potential mechanisms of action. Cancer Res 53: 2239
22. Stolzer T, LaFollette J, Aweeka F, Lin E (1987) Determination of suramin in plasma and urine by ion-paired reverse-phase high-performance liquid chromatography. J Liq Chromatogr 10: 3451
23. Thalmann GN, Sikes RA, Chang SM, Johnston DA, von Eschenbach AC, Chung LW (1996) Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer (see comments). J Natl Cancer Inst 88: 794
24. Vincent TS, Hazen-Martin DJ, Garvin AJ (1996) Inhibition of insulin like growth factor II autocrine growth of Wilms' tumor by suramin in vitro and in vivo. Cancer Lett 103: 49
25. Walz TM, Abdiu A, Wingren S, Smeds S, Larsson SE, Wasteson A (1991) Suramin inhibits growth of human osteosarcoma xenografts in nude mice. Cancer Res 51: 3585
26. Wilding G (1995) Endocrine control of prostate cancer. In: Sidebottom E, Franks LM (eds) Cancer surveys: preventing prostate cancer: screening versus chemoprevention, vol 23. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, p 43